How We Work
Four steps, from diagnosis to the bell
A partner runs your mandate personally. Clear route, clear timetable, clear scope.
Home/Our Process
A partner runs your mandate personally. Clear route, clear timetable, clear scope.
Every mandate is run personally by a partner. Clear route, clear timetable, clear scope.
Business and listing intent, target timeline, current financial and structural position — same-day answer on whether we can take it on
IPO, reverse merger and SPAC laid out on thresholds, timing and cost level, plus our recommended route
Scope and fees set; structure build-out, audit remediation, diligence and drafting all start in parallel
SEC filing and comment responses, roadshow pricing, listing — then 10-K, SOX and follow-ons
The process is not a pitch — it is a sequence of outputs you can hold us to. Every step has a defined deliverable, an owner and a duration, and all of it goes into the scope of work when the mandate is signed.
A direct answer: whether this route works and where it breaks first. We judge on business substance, financial base, cap table and target timetable. No promises — but we will name the parts that do not fit.
The deliverable is a side-by-side comparison: listing thresholds, market-range timing, cost scale and team requirements for an IPO, a reverse merger and a SPAC. The diagnosis is free, fully confidential, and does not require a mandate.
Scope, fee, milestones and named owners on both sides, plus the adviser line-up: auditor, US counsel, underwriter and depositary bank. Group structure, audit remediation and due diligence start in parallel rather than in sequence.
An S-1 or F-1, SEC comment responses, roadshow materials and pricing; after listing, 10-K / 20-F reporting, SOX 404 testing and follow-ons. The deliverables here are documents and dates, not assurances.
Market-range timings are 12–18 months for an IPO, 4–8 months for a reverse merger and 6–10 months for a SPAC merger. The spread is wide because the preparation workload differs enormously — not because the filing step itself is slow.
Decide the listing entity and the offshore / VIE structure, clean up historical equity and related-party positions; the auditor comes in and the last three fiscal years are adjusted and restated to US GAAP. This phase decides whether you file on time.
Build a SOX 404 controls framework that leaves auditable evidence; draft the business and financial sections of the prospectus; put the board, independent directors and audit committee in place; settle the fair-value methodology for share-based compensation.
File the S-1 or F-1. The SEC's first comment letter typically arrives about 30 days after filing, with later rounds following each response. Every round requires consistent positions and traceable numbers. The number of rounds depends on how complete the first disclosure is.
Bookbuilding, management roadshow, pricing and the listing. Pricing depends on the issuance window and comparable valuations — being well prepared does not guarantee the range you want.
10-K / 20-F annual reports, 6-K or 8-K disclosure of material events, first-year SOX 404 testing, lock-up arrangements and follow-ons. Listing is not the finish line; staying listed is a separate, continuing workstream.
These five recur across China-based issuers. None of them is a filing-stage problem — each is planted well before the filing.
Ten minutes: your business and listing intent, target timeline, and your current financial and structural position. We first work out whether the route is viable and which one fits, then how to run it.
No. Thirty minutes, fully confidential. You get IPO, reverse merger and SPAC compared on thresholds, timing and cost level, plus our recommended route.
It depends on the route: 12-18 months for a traditional IPO, 4-8 months for a reverse merger, 6-10 months for a SPAC merger. These are market-practice ranges; actual timing depends on your financial base, sector and the issuance window.
You can, but it costs time. Switching routes means rebuilding the structure, re-running the audit and probably missing the window - which is exactly why we insist on a route diagnosis first.
Yes. 10-K / 20-F ongoing disclosure, SOX 404 controls, investor relations and follow-ons are all part of our banking lines. We do not hand over the keys and leave.
A 30-minute route diagnosis: we assess your revenue scale, financial base and timing window, then set out IPO, reverse merger and SPAC side by side — with indicative timelines and cost levels. Free, and fully confidential.